Cortes-Figueiredo, Filipe
Asseyer, Susanna
Chien, Claudia
Zimmermann, Hanna G.
Ruprecht, Klemens
Schmitz-Hübsch, Tanja
Bellmann-Strobl, Judith
Paul, Friedemann
Morais, Vanessa A.
Funding for this research was provided by:
Fundação para a Ciência e a Tecnologia (FCT/PTDC/MED-NEU/7976/2020, FCT/PTDC/MED-NEU/7976/2020)
Merck KGaA (Restricted Research Grant, Restricted Research Grant)
Deutsche Forschungsgemeinschaft (EXC-2049—390688087, EXC-2049—390688087)
National Multiple Sclerosis Society Lone Star (PP-1712-29466)
Article History
Received: 29 March 2023
Accepted: 20 March 2024
First Online: 29 March 2024
Competing interests
: F.C.F. reports no disclosures relevant to the manuscript. S.A. received speaker’s honoraria from Alexion, Bayer and Roche. C.C. received speaking honoraria from Bayer and research funding from Novartis, unrelated to the current study. H.G.Z. received speaking honoraria from Bayer and Novartis and research funding from Novartis, unrelated to the current study. K.R. received research support from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité, Guthy Jackson Charitable Foundation and Arthur Arnstein Foundation; received travel grants from Guthy Jackson Charitable Foundation. K.R. is a participant in the BIH Clinical Fellow Program funded by Stiftung Charité. T.S.-H. reports no disclosures relevant to the manuscript. J.B.-S. received speaking honoraria and travel grants from Bayer Healthcare, and sanofi-aventis/Genzyme, in addition received compensation for serving on a scientific advisory board of Roche, unrelated to the presented work. F.P. serves as an Associate Editor for Neurology: Neuroimmunology & Neuroinflammation and PLoS ONE, reports speaker honoraria and/or travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, and Celgene, research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion, Merck Serono, German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu), Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis Society of the USA, consultancies for Sanofi-Aventis / Genzyme, Biogen Idec, MedImmune, Shire, and Alexion, and is a member of the steering committee of the OCTIMS study (Novartis). V.A.M. reports no disclosures relevant to the manuscript.